Uterine Fibroids Market 2028 By Type, End Use, and Geography | The Insight Partners

report image

Uterine Fibroids Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Surgical, Hormonal, Embolization, and Others); End Use (Hospital, Ambulatory Surgical Centers, Diagnostic Centers, and Others), and Geography

Report Code: TIPRE00024418 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming


Uterine Fibroids are generally small benign, non-cancerous tumors that grow in the uterus wall. These are cancerous but do not spread. They differ in size, from the minute inch to an area of more than 16 cm. The number of uterine fibroids is about 20%-40% in women through their reproductive ages. Often, these fibroids swell up and make the uterus develop like full visible pregnancy. Mostly, there is a chance of more than one fibroid in the uterus. Indication of uterine fibroids involves heavy menstrual bleeding, frequent urination, pelvic pain, constipation, and backache or leg pain. The circumstances behind the growth of these tumors can be genetic changes, hormonal imbalance, and other reasons. The treatment includes medications that specifically target hormones, embolization, MRI-guided focused ultrasound surgery (FUS), and hysterectomy.


The "Global Uterine Fibroids Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Uterine fibroids market with detailed market segmentation by type, end use, and geography. The report provides key statistics on the market status of the leading Uterine fibroids market players and offers key trends and opportunities in the market.


  •  Based on type, the global Uterine fibroids market is segmented into surgical, hormonal, embolization, others.
  •  On the basis of end use, the market is segmented into hospital, ambulatory surgical centers, diagnostic centers, others.



  •  Rise in the incidences of Uterine Fibroids.
  •  Rise in the demand for minimally or non-invasive uterine fibroid methods.
  •  Growing awareness initiatives related to uterine fibroids diagnosis and treatment.
  •  Technological advancements.


  •  The high treatment cost associated with uterine fibrosis is the major restraining factor for this market.


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Uterine fibroids market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Uterine fibroids market in these regions.


COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

Get more information on this report :


The report covers key developments in the Uterine fibroids market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Uterine fibroids market are anticipated to lucrative growth opportunities in the future with the rising demand for Uterine fibroids in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Uterine fibroids market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Boston Scientific
  •  Cooper Surgical
  •  C.R. Bard
  •  F. Hoffmann-La Roche
  •  GE Healthcare
  •  Karl Storz Endoscopy
  •  Richard Wolf Medical Instruments
  •  Siemens Medical Solutions
  •  AbbVie
  •  AstraZeneca
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Get more information on this report :

The List of Companies

1. Boston Scientific
2. Cooper Surgical
3. C.R. Bard
4. F. Hoffmann-La Roche
5. GE Healthcare
6. Karl Storz Endoscopy
7. Richard Wolf Medical Instruments
8. Siemens Medical Solutions
9. AbbVie
10. AstraZeneca
11. Bayer
12. Eli Lilly
13. GlaxoSmithKline Pharmaceuticals
14. Pfizer
15. Johnson and Johnson
16. Novartis
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount